Focused Pharmacogenomics Panel
Test in Focus
Mayo Clinic Laboratories’ updated focused pharmacogenomics panel uses real-time, PCR testing for targeted genotyping of 10 genes with known associations to medications used to treat a variety of disorders across a spectrum of specialities. In this “A Test in Focus” episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how this innovative assay helps guide providers on choosing the best treatment option for their patients.
“The goal of this panel would be that it should be useful for patients that are either on many different medications or patients where the differential diagnosis is still rather broad, where it's difficult to decide which medication to put the patient on,” Dr. Moyer says “Because these drugs metabolize so many different medications, hopefully this is a panel that, once the patient has it ordered, it can be reused again and again, throughout their care, no matter what specialty they're seeing.”
By including both genotype and phenotype evaluation of those genes with a high level of evidence for metabolic associations to medications, the test enables detailed insights on patients’ genetic dispositions, Dr. Moyer says. “We tried to be really careful and cognizant about making sure that we include all of the alleles that are relevant for various patient populations throughout the world. And I think that makes our tests something that should be useful for years to come.”
Listen to learn more about how our focused pharmacogenomics panel can help guide treatment selection and improve treatment outcomes for patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Submit only 1 of the following specimens:
Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.
In this test-specific episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Bjorn Oskarsson, M.D., a neurologist at Mayo Clinic’s Florida campus, discuss how the neurofilament light chain test available through Mayo Clinic Laboratories helps physicians diagnose neurological disease and assess neuronal damage.